G1 Therapeutics Inc GTHX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GTHX is a good fit for your portfolio.
News
-
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
-
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
-
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
-
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
-
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
Trading Information
- Previous Close Price
- $4.17
- Day Range
- $3.97–4.31
- 52-Week Range
- $1.08–5.00
- Bid/Ask
- $3.92 / $4.17
- Market Cap
- $214.54 Mil
- Volume/Avg
- 732,120 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.61
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 100
- Website
- https://www.g1therapeutics.com
Comparables
Valuation
|
Metric
|
GTHX
|
SWTX
|
SNDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.12 | 4.98 | 3.14 |
Price/Sales | 2.61 | 492.06 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GTHX
SWTX
SNDX
Financial Strength
|
Metric
|
GTHX
|
SWTX
|
SNDX
|
|---|---|---|---|
Quick Ratio | 3.19 | 6.21 | 9.96 |
Current Ratio | 3.87 | 6.41 | 10.00 |
Interest Coverage | −3.71 | — | −1,107.28 |
Quick Ratio
GTHX
SWTX
SNDX
Profitability
|
Metric
|
GTHX
|
SWTX
|
SNDX
|
|---|---|---|---|
Return on Assets (Normalized) | −24.26% | −39.61% | −37.16% |
Return on Equity (Normalized) | −73.10% | −45.43% | −40.25% |
Return on Invested Capital (Normalized) | −26.19% | −49.28% | −44.82% |
Return on Assets
GTHX
SWTX
SNDX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dslgqjpm | Fqgfg | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tvwysrmq | Vcbdcz | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qgdzxvdw | Dxqwzg | $98.1 Bil | |
MRNA
| Moderna Inc | Lnvxtffh | Whj | $39.1 Bil | |
ARGX
| argenx SE ADR | Vljwwyz | Llss | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Rmmfkyb | Xfjz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nrjrpflk | Cxxysq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dtzvptbtl | Kvxrds | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Whvmdyzsq | Cpgcjzf | $12.5 Bil | |
INCY
| Incyte Corp | Xqmcwcqny | Ktkmkk | $11.9 Bil |